BDRX Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chartmill - Mentions: IRBT NCI SUPX ASTI ...

Wondering what's happening in today's pre-market session?

5 days ago - By: Chartmill - Mentions: IRBT NCI RILY PLAG ...

Get insights into the top gainers and losers of Monday's after-hours session.

2 days ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Pricing of $10 Million Public Offering

5 days ago - By: Chartmill - Mentions: ASTI DXLG YCBD RZLT ...

Unusual volume stocks in Monday's session

5 days ago - By: Chartmill - Mentions: IRBT NCT ASNS PCSA ...

Monday's session: top gainers and losers

10 days ago - By: Chartmill - Mentions: IRBT LAKE BEAT PLAB ...

These stocks are moving in today's session

10 days ago - By: Chartmill - Mentions: IBIO RETO OCG SNTI ...

The trading volume of these stocks is deviating from the norm in today's session.

10 days ago - By: Chartmill - Mentions: LAKE BEAT MIND PLAB ...

These stocks that are showing activity before the opening bell on Wednesday.

11 days ago - By: Chartmill - Mentions: ALEX TROX CMCT CETX ...

Keep an eye on the top gainers and losers in Tuesday's session.

11 days ago - By: Chartmill - Mentions: ALEX TROX CMCT CETX ...

What's going on in today's session

11 days ago - By: Chartmill - Mentions: STAA ALEX TROX CMCT ...

Traders are paying attention to the gapping stocks in Tuesday's session.

11 days ago - By: Chartmill - Mentions: ALEX WHLR CMCT CAL ...

What's going on in today's pre-market session

12 days ago - By: Chartmill - Mentions: CEP RPRX FGL CMCT ...

What's going on in today's after hours session

12 days ago - By: Chartmill - Mentions: NBY IBIO GURE WHLR ...

Let's take a look at the stocks that are in motion in today's session.

12 days ago - By: Chartmill - Mentions: GURE WHLR WVE GNLN ...

Wondering what's happening in today's pre-market session?

19 days ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

a month ago - By: Biodexa Pharmaceuticals PLC

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

a month ago - By: Benzinga - Mentions: ZYXI ITRM ARVN OLMA ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

a month ago - By: Benzinga - Mentions: CANF IFRX ARVN OLMA ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

2 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

3 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

3 months ago - By: Biodexa Pharmaceuticals PLC

Interim results for the six months ended June 30, 2025

3 months ago - By: ACCESS Newswire

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

4 months ago - By: Zacks Investment Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

4 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

5 months ago - By: Biodexa Pharmaceuticals PLC

ADR Ratio Change Effective

5 months ago - By: ACCESS Newswire

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

5 months ago - By: Biodexa Pharmaceuticals PLC

ADR Ratio Change

5 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

6 months ago - By: Biodexa Pharmaceuticals PLC

BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock News

BDRX Latest News, Press Relases and Analysis

Wondering what's happening in today's pre-market session?

Get insights into the top gainers and losers of Monday's after-hours session.

Biodexa Announces Pricing of $10 Million Public Offering

Unusual volume stocks in Monday's session

Monday's session: top gainers and losers

These stocks are moving in today's session

The trading volume of these stocks is deviating from the norm in today's session.

These stocks that are showing activity before the opening bell on Wednesday.

Keep an eye on the top gainers and losers in Tuesday's session.

What's going on in today's session

Traders are paying attention to the gapping stocks in Tuesday's session.

What's going on in today's pre-market session

What's going on in today's after hours session

Let's take a look at the stocks that are in motion in today's session.

Wondering what's happening in today's pre-market session?

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting